Evidence map›Paper›PMID 33173540›Full record

ArticleFrontiers in genetics2020

The Value of Mouse Models of Rare Diseases: A Spanish Experience.

Silvia Murillo-Cuesta, Rafael Artuch, Fernando Asensio, Pedro de la Villa, Mara Dierssen, Jose Antonio Enríquez, Cristina Fillat, Stéphane Fourcade, Borja Ibáñez, Lluis Montoliu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in Europe.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Review
  4. Article
  5. Modelling phenotypes, variants and pathomechanisms of syndromic diseases in different systems.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024
    Article
  6. Rarer dementias, limited options, and unaddressed needs.International psychogeriatrics · 2024
    Article
  7. A review of fatty acid oxidation disorder mouse models.Molecular genetics and metabolism · 2024
    Review
  8. Article
  9. INFRAFRONTIER: mouse model resources for modelling human diseases.Mammalian genome : official journal of the International Mammalian Genome Society · 2023
    Review
  10. Article
  11. Review
  12. The mouse resource at National Resource Center for Mutant Mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2022
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Silvia Murillo-CuestaBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Rafael ArtuchBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Fernando AsensioGregorio Marañón Institute for Health Research (IISGM), Madrid, Spain.
Pedro de la VillaFaculty of Medicine, University of Alcalá (UAH), Alcalá de Henares, Spain.
Mara DierssenBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Jose Antonio EnríquezSpanish National Center for Cardiovascular Research (CNIC), Institute of Health Carlos III, Madrid, Spain.
Cristina FillatBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Stéphane FourcadeBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Borja IbáñezSpanish National Center for Cardiovascular Research (CNIC), Institute of Health Carlos III, Madrid, Spain.
Lluis MontoliuBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Eduardo OliverSpanish National Center for Cardiovascular Research (CNIC), Institute of Health Carlos III, Madrid, Spain.
Aurora PujolBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Eduardo SalidoBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Mario VallejoInstituto de Investigaciones Biomédicas Alberto Sols (IIBM), Consejo Superior de Investigaciones Científicas/Universidad Autónoma de Madrid, Madrid, Spain.
Isabel Varela-NietoBiomedical Research Networking Center on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Instituto de Salud Carlos III · ESCentre for Biomedical Network Research on Rare Diseases · ESCentre for Genomic Regulation · ESCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable · ESCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESCentro Nacional de Biotecnología · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario Fundación Jiménez Díaz · ESInstitució Catalana de Recerca i Estudis Avançats · ESUniversidad Autónoma de Madrid · ESUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal models are invaluable for biomedical research, especially in the context of rare diseases, which have a very low prevalence and are often complex. Concretely mouse models provide key information on rare disease mechanisms and therapeutic strategies that cannot be obtained by using only alternative methods, and greatly contribute to accelerate the development of new therapeutic options for rare diseases. Despite this, the use of experimental animals remains controversial. The combination of respectful management, ethical laws and transparency regarding animal experimentation contributes to improve society's opinion about biomedical research and positively impacts on research quality, which eventually also benefits patients. Here we present examples of current advances in preclinical research in rare diseases using mouse models, together with our perspective on future directions and challenges.

Indexed as

animal modelsethicsnovel therapiesorphan diseasespreclinical researchtransparency

Identifiers

PMID33173540
PMCPMC7591746
OpenAlexW3092682211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.